Growth hormone replacement decreases plasma levels of matrix metalloproteinases (2 and 9) and vascular endothelial growth factor in growth hormone-deficient individuals

Circulation

Volumn 109, Issue 20, 2004, Pages 2405-2410

  Randeva, Harpal S ^a   Lewandowski, Krzysztof C ^a   Komorowski, Jan ^b   Murray, Robert D ^c   O'Callaghan, Chris J ^d   Hillhouse, Edward W ^a   Stepien, Henryk ^b   Shalet, Stephen M ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; Cardiovascular diseases; Growth substances; Metalloproteinases; Vasculature

Indexed keywords

GELATINASE A; GELATINASE B; GROWTH HORMONE; SOMATOMEDIN C; VASCULOTROPIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DEVICE; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

ADULT; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2542466624     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000129763.51060.77     Document Type: Article

References (37)

1. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336:285-288.
2. Rosen T, Eden S, Larson G, et al. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 1993;129:195-200.
3. Colao A, Marzullo P, Di Somma C, et al. Growth hormone and the heart. Clin Endocrinol (Oxf). 2001;54:137-154.
4. Evans LM, Davies JS, Goodfellow J, et al. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1999;50:457-464.
5. Pfeifer M, Verhovec R, Zizek B, et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab. 1999;84:453-457.
6. Komorowski J, Pasieka Z, Jankiewicz-Wika J, et al. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid. 2002;12:655-662.
7. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
8. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab. 1998;18:1163-1172.
9. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002;106:1543-1549.
10. Creemers EE, Cleutjens JP, Smits JF, et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001;89:201-210.
11. Shah PK. Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Rev. 2000;8:31-39.
12. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368-372.
13. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
14. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
15. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
16. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res. 1998;83:832-840.
17. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
18. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98:1667-1675.
19. Colao A, di Somma C, Cuocolo A, et al. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab. 2001;86:1874-1881.
20. Murray RD, Wieringa GE, Lissett CA, et al. Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome. Clin Endocrinol (Oxf). 2002;56:525-532.
21. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomized, controlled clinical trial. Ann Intern Med. 2000;133:111-122.
22. Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke. 2000;31:40-47.
23. Loftus IM, Naylor AR, Bell PR, et al. Plasma MMP-9 - a marker of carotid plaque instability. Eur J Vasc Endovasc Surg. 2001;21:17-21.
24. Rouet-Benzineb P, Buhler JM, Dreyfus P, et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail. 1999;1:337-352.
25. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism: West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357:425-431.
26. Juul A, Scheike T, Davidsen M, et al. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939-944.
27. Anne-Valerie R, Christelle D, Yannick F, et al. Human growth hormone stimulates proteinase activities of rabbit bone cells via IGF-I. Biochem Biophys Res Commun. 2000;268:875-881.
28. Wilson MJ, Sellers RG, Wiehr C, et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol. 2002;191:208-216.
29. Lupia E, Elliot SJ, Lenz O, et al. IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Diabetes. 1999;48:1638-1644.
30. Pattison ST, Melrose J, Ghosh P, et al. Regulation of gelatinase-A (MMP-2) production by ovine intervertebral disc nucleus pulposus cells grown in alginate bead culture by transforming growth factor-beta(1) and insulin like growth factor-1. Cell Biol Int. 2001;25:679-689.
31. Punglia RS, Lu M, Hsu J, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 1997;46:1619-1626.
32. Nagai Y, Ando H, Nohara E, et al. Plasma levels of vascular endothelial growth factor in patients with acromegaly. Horm Metab Res. 2000;32:326-329.
33. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
34. Tamura M, Sebastian S, Gurates B, et al. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. J Clin Endocrinol Metab. 2002;87:3504-3507.
35. Bouloumie A, Sengenes C, Portolan G, et al. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes. 2001;50:2080-2086.
36. Lijnen HR, Maquoi E, Hansen LB, et al. Matrix metalloproteinase inhibition impairs adipose tissue development in mice. Arterioscler Thromb Vasc Biol. 2002;22:374-379.
37. Randeva HS, Murray RD, Lewandowski KC, et al. Differential effects of GH replacement on the components of the leptin system in GH-deficient individuals. J Clin Endocrinol Metab. 2002;87:798-804.